Phase i study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease

Acta Pharmacologica Sinica

Volumn 34, Issue 7, 2013, Pages 976-982

  Jia, Jing Ying ^a   Zhao, Qian Hua ^b   Liu, Yun ^a   Gui, Yu Zhou ^c   Liu, Gang Yi ^a   Zhu, Da Yuan ^c   Yu, Chen ^a   Hong, Zhen ^b  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AChE inhibitor; Alzheimer's disease; drug tolerance; huperzine A; pharmacokinetics; prodrug; ZT 1

Indexed keywords

HUPERZINE A; NOOTROPIC AGENT; PLACEBO; UNCLASSIFIED DRUG; ZT 1;

ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINUS BRADYCARDIA; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ALKALOIDS; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; PRODRUGS; SESQUITERPENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881450088     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.7     Document Type: Article

References (23)

1. Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clin Ther 2001; 23: 13-24.
2. Jiang H, Luo X, Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease. Curr Med Chem 2003; 10: 2231-52.
3. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-47.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
5. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22-6.
6. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
7. Ma X, Gang DR. In vitro production of huperzine A, a promising drug candidate for Alzheimer's disease. Phytochemistry 2008; 69: 2022-8.
8. Tang XC, Han YF, Chen XP, Zhu XD. Effects of huperzine A on learning and the retrieval process of discrimination performance in rats. Zhongguo Yao Li Xue Bao 1986; 7: 507-11.
9. Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276-85.
10. Tang XC, Kindel GH, Kozikowski AP, Hanin I. Comparison of the effects of natural and synthetic huperzine - A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol 1994; 44: 147-55.
11. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996; 8: 97-101.
12. Li Y, Hu GY. Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons. Neurosci Lett 2002; 324: 25-8.
13. Zhao Q, Tang XC. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol 2002; 455: 101-7.
14. Tang XC, Han YF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese Herb. CNS Durg Rev 1999; 5: 281-300.
15. Liang YQ, Tang XC. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 2004; 361: 56-9.
16. Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C, et al. Tacrine derivatives and Alzheimer's disease. Curr Med Chem 2010; 17: 1825-38.
17. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995; 274: 767-70.
18. Ma X, Gang DR. The Lycopodium alkaloids. Nat Prod Rep 2004; 21: 752-72.
19. Sun MX, Zhao J, Tan CH, Zhu DY, Xiao K. Progress in studies of prevention drugs of neural toxicity. Chin J Pharmacol Toxicol 2011; 25: 497-8.
20. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1-26.
21. Powers J. Statistical analysis of pharmacokinetic data. J Veter Pharmacol Ther 1990; 13: 113-20.
22. Csajka C, Buclin T, Nicolas V, Grosgurin P, Porchet H, Scalfaro P, et al. Population pharmacokinetics of ZT-1 and its active metabolite huperzine A after intravenous, oral and subcutaneous administration in healthy volunteers. SGS Biopharma SA, Study DEBZT-107, Clin Study Report; 2004.
23. Li C, Du F, Yu C, Xu X, Zheng J, Xu F, et al. A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 651-6.